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Background
The primary neuropathological characteristics of AD
include intracellular, filamentous inclusions of hyperpho-
sphorylated microtubule associated protein tau (MAPT) in
neurons (neurofibrillary tangles, NFTs) and extracellular
deposits of the beta-amyloid peptide (A-Beta) in senile pla-
ques. While A-Beta plaques are unique to AD, NFTs are
observed in a wide variety of neurodegenerative diseases,
including AD, frontotemporal dementia, cortical basal
degeneration and other disorders, collectively termed
tauopathies. Microglia, the primary immune effector cells
in the brain, continually monitor the tissue parenchyma
for pathological alterations and become activated in AD
and other tauopathies. Increasing evidence suggests that
microglia contribute to the pathopysiology of AD includ-
ing; correlational studies in human AD and mouse models,
retrospective epidemiological studies demonstrating that
use of nonsteroidal anti-inflammatory drugs (NSAIDs)
substantially reduces AD risk, genome-wide association
studies of human AD and studies utilizing genetically
modified mouse models. Neuronal-microglial communica-
tion through the chemokine fractalkine (CX3CL1) and its
cognate receptor, CX3CR1, plays a critical role in neuroin-
flammation and neuroprotection. First, CX3CL1 is highly
expressed by neurons while CX3CR1 is only expressed by
microglia within the CNS. Second, CX3CL1 is neuropro-
tective in models of neuroinflammation. Finally, studies of
Cx3cr1 knockout mice revealed enhanced neurodegenera-
tion in mouse models of amyotrophic lateral sclerosis
(ALS) and Parkinson’s Disease (PD).
Methods
To examine the role of CX3CL1-CX3CR1 signaling in
Alzheimer’s disease, we examined the effects of CX3CR1
deficiency on both A-Beta and MAPT pathologies in the
APPPS1 (and R1.40) and hTau mouse models of AD,
respectively. Mice were aged and examined for altera-
tions in gene expression, biochemistry, neuropathology
and behavior.
Results
Surprisingly, CX3CR1 deficiency resulted in a gene dose-
dependent reduction in A-Beta deposition in both the
APPPS1 and R1.40 transgenic mouse models of A-Beta
deposition that was associated with altered microglial acti-
vation, reduced numbers of plaque associated microglia
and yet enhanced removal of A-Beta. Analysis of CX3CR1
deficient microglia revealed an enhanced capacity for pha-
gocytosis of A-Beta and also increased expression of
matrix metalloproteinase 9 (MMP9), an A-beta degrading
protease. By contrast, CX3CR1 deficiency in the hTau
mouse model of MAPT pathology resulted in enhanced
microglial activation and phagocytosis, phosphorylation
and aggregation of MAPT and behavioral impairments.
Additional in vitro experiments demonstrate that micro-
glial activation and CX3CR1 deficiency elevates the level
of active p38 MAPK and enhances MAPT hyperphosphor-
ylation within neurons that can be blocked by administra-
tion of a specific p38 MAPK inhibitor. In vivo adoptive
transfer experiments in which microglia were purified
from CX3CR1 deficient hTau mice and transferred to
non-transgenic controls, revealed enhanced MAPT phos-
phorylation demonstrating the cell autonomous nature of
the signal.
Conclusion
Our results suggest that CX3CR1 deficiency has opposing
effects on the development of the two primary pathologies
observed in AD and suggests that “anti-inflammatory”
therapies may have opposite effects on AD pathologies at
different stages of disease progression.
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